A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/1998
10/01/1998	WO1998027969A3 Antimicrobial phenazine compounds
10/01/1998	WO1998027931A3 Salts of acetaminophen
10/01/1998	WO1998027206A3 POLYPEPTIDES OF THE 'BASIC-HELIX-LOOP-HELIX' bHLH FAMILY, CORRESPONDING NUCLEIC ACID SEQUENCES
10/01/1998	WO1998025593A3 2-cyclopenten-1-one and its derivatives as inhibitors of the nf-kb factor
10/01/1998	WO1998024427A3 Compositions and methods for treating or preventing inflammatory diseases
10/01/1998	WO1998024422A3 Method for controlling body fat and/or body weight in animals and pharmaceutical compositions for use therein
10/01/1998	DE19713263A1 Arzneimittel, vorzugsweise zur Entzündungshemmung Drug, preferably for suppression of inflammation
10/01/1998	DE19713000A1 New heterocyclic compounds are adhesion receptor antagonists
10/01/1998	DE19712977A1 Use of gamma-aminobutyric acid
10/01/1998	DE19712976A1 Use of gamma-aminobutyric acid as cyto-protective agent
10/01/1998	DE19712636A1 Use of inhibitor of sodium/proton exchange to treat hyperlipidaemia
10/01/1998	DE19712493A1 Pharmaceutical composition comprises iron calcium poly:ate
10/01/1998	DE19712488A1 Steroidsulfamate, Verfahren zu ihrer Herstellung und Anwendung derselben Steroidsulfamate, processes for their preparation and use thereof
10/01/1998	DE19712410A1 Verwendbarkeit des antibakteriellen Wirkstoffes Triclocarban in Flüssigseifen Usability of the antibacterial agent triclocarban in liquid soaps
10/01/1998	CA2484922A1 Liposomes containing oligonucleotides
10/01/1998	CA2320287A1 Fungal sulphur source and method of using the same
10/01/1998	CA2293591A1 Antisense inhibition of angiogenin expression
10/01/1998	CA2285530A1 Di-aryl ethers and their derivatives as anti-cancer agents
10/01/1998	CA2285480A1 Screening method for proline-rich proteins
10/01/1998	CA2285439A1 Aryl- or heteroarylsulfonamide substituted hydroxamic acid derivates, process for their preparation and their use as pharmaceuticals
10/01/1998	CA2285394A1 Antimicrobial prevention and treatment of human immunedeficiency virus and other infectious diseases
10/01/1998	CA2285391A1 Methods and compositions for treatment of ovarian cancer
10/01/1998	CA2285297A1 Mediation of circadian rhythms
10/01/1998	CA2285178A1 Bone marrow as a site for transplantation
10/01/1998	CA2284992A1 Use of chelerythrine and radiation for tumor therapy
10/01/1998	CA2284776A1 Use of the antibacterial active substance triclocarbane in liquid soaps
10/01/1998	CA2284757A1 Method for treatment of chronic bronchitis
10/01/1998	CA2284747A1 Tetrahydropyrido compounds
10/01/1998	CA2284719A1 Nasal melatonin composition
10/01/1998	CA2284710A1 Quinoline-2-carboxylic acid derivative and its use as excitatory amino acids antagonist
10/01/1998	CA2284705A1 Chemically and thermally stable norastemizole formulations
10/01/1998	CA2284642A1 Methods and compositions for diagnosis and treatment of breast cancer
10/01/1998	CA2284633A1 Chemokines that inhibit immunodeficiency virus infection and methods based thereon
10/01/1998	CA2284620A1 Dithiane and dithiolane nitrato derivatives
10/01/1998	CA2284550A1 87 human secreted proteins
10/01/1998	CA2284483A1 Mixtures of at least two reverse transcriptase inhibitors and hydroxycarbamide, in particular for inhibiting retroviral spread
10/01/1998	CA2284263A1 Difluoronucleoside phosphonic acids and derivatives thereof
10/01/1998	CA2284200A1 Novel pyridine derivatives and pharmaceutical compositions containing them
10/01/1998	CA2284192A1 Retinoid related molecules for the treatment of non-insulin dependent diabetes mellitus
10/01/1998	CA2283704A1 Thrombin inhibitors
10/01/1998	CA2283230A1 Method of making arylamino triazolopyridines
10/01/1998	CA2282531A1 Gastrointestinal mucosa-adherent pharmaceutical composition
10/01/1998	CA2282320A1 2,3-dihydrofuro¬3,2-b\|pyridin, preparation and application thereof in therapy
10/01/1998	CA2282275A1 Method of treatment of migraine
10/01/1998	CA2275389A1 Pharmaceutically active tricyclic amines
10/01/1998	CA2255765A1 Antigenic fusionprotein carrying gal.alpha.1,3gal epitopes
10/01/1998	CA2232461A1 Ortho-substituted benzoylguanidines, process for their preparation, their use as a medicament or diagnostic, and medicament comprising them
09/1998
09/30/1998	EP0867515A1 Process for the isolation of a pharmaceutically acceptable alkali metal salt of clavulanic acid
09/30/1998	EP0867509A2 Tumor necrosis related receptor, TR5
09/30/1998	EP0867452A1 Cervical canal maturing agent
09/30/1998	EP0867447A1 Water-soluble extract of asiaticoside and madecassoside from centella asiatica and isolating method thereof
09/30/1998	EP0867438A1 Rapamycin derivatives and their use, particularly as immunosuppressants
09/30/1998	EP0867436A1 N-aryl-piperidine derivatives and their use as 5-HT1B receptor ligands
09/30/1998	EP0867432A2 Fused N-heterocyclic compounds substituted with benzyloxy, process for their preparation and their use as bradykinin receptor antagonists
09/30/1998	EP0867430A2 Glutamic acid derivatives and pharmaceutical compositions for the treatment of central nervous system disorders
09/30/1998	EP0867192A2 Combinatory compositions for the treatment of dementia containing at least a compound having acetylcholinesterase-inhibitory or muscarinic activity and a compound that enhances the endogenous extracellular adenosine levels
09/30/1998	EP0867186A1 A long acting injectable parasiticidal composition and the process for its preparation
09/30/1998	EP0867185A1 Platelet function potentiator and method of curing platelet dysfunction
09/30/1998	EP0867184A1 Use of tiagabine for the treatment of sleep disorders
09/30/1998	EP0867182A2 The use of certain NK-1 receptor antagonists for the manufacture of a medicament for treating emesis
09/30/1998	EP0867181A1 Nasal melatonin composition
09/30/1998	EP0867180A1 Vascular permeation inhibitor
09/30/1998	EP0867179A1 Composition of L-DOPA esters
09/30/1998	EP0867178A1 Non-allosteric GABA A agonists for treating sleep disorders
09/30/1998	EP0867177A1 Free-flowing dried particles
09/30/1998	EP0867175A1 Complexes of gamma-cyclodextrins and retinol or retinol-derivatives and manufacturing process thereof and their use
09/30/1998	EP0866874A1 Process for the preparation of materials with a high content of long chain polyunsaturated fatty acids
09/30/1998	EP0866871A1 Compositions and method for stimulating antibody release by b lymphocytes
09/30/1998	EP0866865A1 Chimeric oligomers having an rna-cleavage activity
09/30/1998	EP0866864A2 Antifungal proteins
09/30/1998	EP0866863A1 Antifungal proteins
09/30/1998	EP0866861A2 Molecular cloning and characterization of molecules related to relaxin and the insulin family of ligands
09/30/1998	EP0866860A2 Novel tyrosine kinase receptors and ligands
09/30/1998	EP0866852A1 Tissue-specific and target rna-specific ribozymes
09/30/1998	EP0866851A1 Tumour vaccine and process for the preparation thereof
09/30/1998	EP0866814A1 Copolymers of carboxylic acids and multiply olefinically unsaturated carboxylic acid derivatives and their use as thickeners and dispergents
09/30/1998	EP0866806A1 Method of mobilizing hematopoietic stem cells
09/30/1998	EP0866804A2 Cosmetic preparations containing vertebrate proteins and having antibacterial, antimycotical and antiviral action
09/30/1998	EP0866801A1 Cyclopeptolides
09/30/1998	EP0866800A2 Antineoplastic peptides
09/30/1998	EP0866793A1 Nitroimidazole antibacterial compounds and methods of use thereof
09/30/1998	EP0866791A1 Diaminopyrimidines, pharmaceutical compositions containing them and their use as antibacterial
09/30/1998	EP0866790A1 3-benzylaminopyrrolidines and -piperidines as tachykinin receptor antagonists
09/30/1998	EP0866726A1 Pulmonary administration of dry powder alpha 1-antitrypsin
09/30/1998	EP0866722A1 Improved formulation for administration of steroid compounds
09/30/1998	EP0866721A1 Targeted adenovirus vectors
09/30/1998	EP0866720A1 Methods of increasing lean tissue mass using ob protein compositions
09/30/1998	EP0866719A1 Method for treating retinal ganglion cell injury using glial cell line-derived neurotrophic factor (gdnf) protein product
09/30/1998	EP0866718A1 Use of toxin peptides and/or affinity handles for the delivering compounds into cells
09/30/1998	EP0866716A1 Methods of treating disorders of non-visual sensory epithelia
09/30/1998	EP0866713A1 Administration media for analgesic, anti-inflammatory and anti-pyretic drugs containing nitrous oxide and pharmaceutical compositions containing such media and drugs
09/30/1998	EP0866712A1 Antineoplastic methods and compositions employing optically pure (-)-fotemustine
09/30/1998	EP0866711A1 Method of inhibiting sleep apnea
09/30/1998	EP0866710A1 Compositions and methods for treating bone deficit conditions
09/30/1998	EP0866709A1 1,2,4-benzotriazine oxides formulations
09/30/1998	EP0866707A1 Cisapride sustained release
09/30/1998	EP0866706A1 Treatment of traumatic brain injury
09/30/1998	EP0866705A1 Fibrinogen receptor antagonists
09/30/1998	EP0866704A1 Use of 1-(2-naphth-2-ylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine for preparing drugs for treating amyotrophic lateral sclerosis
09/30/1998	EP0866703A1 Use of 2-aminobenzothiazoles for treating parkinson's disease and parkinsonian syndromes

1 ... 6601 6602 6603 6604 6605 6606 6607 6608 6609 6610 6611 6612 6613 6614 6615 6616 6617 6618 6619 6620 6621 ... 7860